The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Guidelines for the management of growth failure in childhood inflammatory bowel disease
Open accessAbstract
Around 1 in 4 patients with inflammatory bowel disease (IBD) present in childhood, the majority around the time of their pubertal growth spurt. This presents challenges over and above those of managing IBD in adults as this period is a time of dramatic psychological and physical transition for a child. Growth and nutrition are key priorities in the management of adolescents and young adults with IBD. Growth failure in IBD is characterized by delayed skeletal maturation and a delayed onset of puberty, and is best described in terms of height-for-age standard deviation score (Z score) or by variations in growth velocity over a period of 3-4 months. Growth failure is common at presentation in Crohn's disease (CD), but less common in ulcerative colitis (UC). The etiology of growth failure is multifactorial. Principal determinants, however, include the inflammatory process per se, with proinflammatory cytokines (e.g., IL-1beta, IL-6) being directly implicated. Furthermore, poor nutrition and the consequences of prolonged corticosteroid use also contribute to the significant reduction in final adult height of almost 1 in 5 children. Initially a prompt, where possible steroid-free, induction of remission is indicated. The ideal is then to sustain a relapse-free remission until growth is complete, which is often not until early adulthood. These goals can often be achieved with a combination of exclusive enteral nutrition (EEN) and early use of immunosuppressants. The advent of potent and efficacious biological agents considerably improves the range of growth-sparing interventions available to children around puberty, although well-timed surgery remains another highly effective means of achieving remission and significant catch-up growth. We carried out a systematic review of publications to identify the best available evidence for managing growth failure in children with IBD. Despite the paucity of high-quality publications, sufficient data were available in the literature to allow practical, evidence-based where possible, management guidelines to be formulated. Although there is clear evidence that exclusive enteral nutrition achieves mucosal healing, its effect on growth has only been assessed at 6 months. In contrast to corticosteroids, EEN has no negative effect on growth. Corticosteroids remain the key therapy responsible for medication-induced growth impairment, although the use of budesonide in selected patients may minimize the steroid effect on dividing growth plates. Immunosuppressants have become a mainstay of treatment in children with IBD, and are being used earlier in the disease course than ever before. However, there are currently no long-term data reporting better growth outcome if these agents are introduced very soon after diagnosis. In comparison, recent data from a large prospective trial of infliximab in children with moderate to severe CD suggested significant catch-up growth during the first year of regular infusions. The only other intervention that has documented clear catch-up growth has been surgical resection. Resection of localized CD, in otherwise treatment-resistant children, early in the disease process achieves clear catch-up growth within the next 6 months. There are no data available that growth hormone improves final adult height in children with CD. In conjunction with expert endocrinological support, pubertal delay, more common in boys, may be treated with parenteral testosterone if causing significant psychological problems. The optimal management of children and adolescents requires a multidisciplinary approach frequently available within the pediatric healthcare setting. Dedicated dietetic support, along with nurse-specialist, child psychologist, and with closely linked medical and surgical care will likely achieve the best possible start for children facing a lifetime of chronic gut disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
Frøslie, K. F., Jahnsen, J., Moum, B. A., & Vatn, M. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.051 · Cited by 1,121
Endoscopic monitoring of Crohn's disease treatment: A prospective, randomized clinical trial
Landi, B., Anh, T. N., Cortot, A., Soule, J. C., Rene, E., Gendre, J. P., Bories, P., See, A., Metman, E. H., Florent, C., et al. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91725-j · Cited by 261
Leonard, M. B., Feldman, H. I., Shults, J., Zemel, B. S., Foster, B. J., & Stallings, V. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040367 · Cited by 206
Cited by
Levine, A., Griffiths, A., Markowitz, J., Wilson, D. C., Turner, D., Russell, R. K., Fell, J., Ruemmele, F. M., Walters, T., Sherlock, M., et al. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21493 · Cited by 1,512
Self-citationVan Assche, G., Dignass, A., Reinisch, W., van der Woude, C. J., Sturm, A., De Vos, M., Guslandi, M., Oldenburg, B., Dotan, I., Marteau, P., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.09.009 · Cited by 894
Inflammatory Bowel Disease in Children and Adolescents
Rosen, M. J., Dhawan, A., & Saeed, S. A. (2015) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2015.1982 · Cited by 788
White, J. V., Guenter, P., Jensen, G., Malone, A., & Schofield, M. (2012) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2012.03.012 · Cited by 751
ESPEN guideline: Clinical nutrition in inflammatory bowel disease
Forbes, A., Escher, J., Hébuterne, X., Kłęk, S., Krznaric, Z., Schneider, S., Shamir, R., Stardelova, K., Wierdsma, N., Wiskin, A. E., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.12.027 · Cited by 625
RetractedAn Update on Inflammatory Bowel Disease
Sairenji, T., Collins, K. L., & Evans, D. V. (2017) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2017.07.010 · Cited by 499
Becker, P., Carney, L. N., Corkins, M. R., Monczka, J., Smith, E., Smith, S. E., Spear, B. A., White, J. V., Academy of Nutrition and Dietetics, & American Society for Parenteral and Enteral Nutrition (2015) · Nutrition in Clinical Practice · doi:10.1177/0884533614557642 · Cited by 393
ESPEN guideline on Clinical Nutrition in inflammatory bowel disease
Bischoff, S. C., Bager, P., Escher, J., Forbes, A., Hébuterne, X., Hvas, C. L., Joly, F., Klek, S., Krznaric, Z., Ockenga, J., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2022.12.004 · Cited by 367
ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease
Bischoff, S. C., Escher, J., Hébuterne, X., Kłęk, S., Krznaric, Z., Schneider, S., Shamir, R., Stardelova, K., Wierdsma, N., Wiskin, A. E., et al. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2019.11.002 · Cited by 351
Becker, P. J., Nieman Carney, L., Corkins, M. R., Monczka, J., Smith, E., Smith, S. E., Spear, B. A., & White, J. V. (2014) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2014.08.026 · Cited by 320
Diet and inflammatory bowel disease: the Asian Working Group guidelines
Sood, A., Ahuja, V., Kedia, S., Midha, V., Mahajan, R., Mehta, V., Sudhakar, R., Singh, A., Kumar, A., Puri, A. S., et al. (2019) · Indian Journal of Gastroenterology · doi:10.1007/s12664-019-00976-1 · Cited by 54
Metadata
- Authors
- Heuschkel, R., Salvestrini, C., Beattie, M. R., Hildebrand, H., Walters, T., & Griffiths, A.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06
- Volume
- 14
- Issue
- 6
- Pages
- 839-849
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2077106621
- Cited by
- 244
- References
- 3
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.